TNF and rheumatoid arthritis: All RA subjects were receiving oral disease-modifying anti-rheumatic drugs (DMARDs) and/or biologic therapy (primarily TNFα antagonists), with 17% on biologic monotherapy, 44% on oral DMARDs only and 38% receiving combination therapy.